Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Piramal Pharma Limited ( (IN:PPLPHARMA) ) has shared an update.
Piramal Pharma Limited’s board has approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025. For the December quarter, standalone revenue from operations stood at ₹1,195.81 crore, slightly lower than the year-ago period, while total income was ₹1,291.96 crore. Net profit after tax rose to ₹128.91 crore from ₹118.80 crore a year earlier, despite a one-off charge of ₹26.94 crore relating to the impact of new labour codes, and total comprehensive income for the quarter reached ₹133.45 crore versus ₹115.27 crore last year. For the nine-month period, revenue from operations was ₹3,292.95 crore compared with ₹3,595.91 crore in the prior year period, but net profit came in higher at ₹438.38 crore versus ₹414.13 crore, with basic earnings per share at ₹3.31. The results, which show improved profitability amid softer topline, underscore the company’s efforts to manage costs and maintain earnings momentum, and will be published in newspapers and on the company’s website in line with regulatory requirements.
More about Piramal Pharma Limited
Piramal Pharma Limited is an India-based pharmaceutical company engaged in manufacturing and marketing pharmaceutical products and solutions. The company operates in formulations and related pharma segments, serving domestic and international markets, and is listed on both BSE and NSE under the symbol PPLPHARMA.
Average Trading Volume: 222,676
Technical Sentiment Signal: Sell
Current Market Cap: 201.2B INR
See more data about PPLPHARMA stock on TipRanks’ Stock Analysis page.